Abstract
The synthetic peptide N-benzoyl-L-tyrosyl- p-aminobenzoic acid was tested in vitro and in vivo for its chymotrypsin specificity. Comparative kinetic tests with bovine chymotrypsin and human pancreatic juice, as well as clearance tests with p-aminobenzoic acid (PABA), made this peptide seem suitable for an indirect pancreatic-function test. A testing scheme was set up for clinical use which has yielded promising preliminary results. While in 31 out of 32 healthy subjects there were normal PABA excretion rates in the urine collected over six hours, the test correlated well in 15 out of 16 cases of definite pancreatic disorder. The percentage dose excretion of PABA in the urine collected over six hours gave good correlations with the one-hour amount of chymotrypsin in the pancreozymin-secretin-test and with the concentration of chymotrypsin in the feces. These preliminary results make this test appear an appropriate screening method for pancreatopathy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
